May 14, 2014
Achieve is conducting a Phase 2b, multi-center study of the efficacy and safety of a topically applied experimental gel in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee following cessation of pain therapy.
May 13, 2014
Avail is conducting a phase 1, single dose, parallel group study to evaluate the pharmacokinetics of an experimental drug in subjects with impaired renal function.
Apr 16, 2014
Achieve is conducting a randomized, active and placebo-controlled study to evaluate the efficacy and safety of an experimental drug for preventing flares and reducing serum uric acid in patients with gout.
Apr 15, 2014
Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to participants with type 2 diabetes mellitus.
Mar 13, 2014
Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the safety and efficacy of an experimental ointment for qualified participants with primary osteoarthritis (OA) affecting a single knee joint.
Mar 11, 2014
Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE).
Feb 12, 2014
Avail is conducting a randomized, placebo-controlled study to assess the efficacy, long-term safety and tolerability of a new high cholesterol drug in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events.
Feb 11, 2014
Achieve is conducting a placebo-controlled study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a new drug in the treatment of subjects with hypertension and type 2 diabetes.
Jan 25, 2014
Achieve is conducting a placebo-controlled study of the efficacy, tolerability and safety of a new high cholesterol drug in reducing the occurrence of major cardiovascular (CV) events in high risk subjects with high cholesterol.
Jan 22, 2014
Avail is conducting a randomized study to evaluate the safety and efficacy of a new hepatitis drug in combinations with simeprevir and/or ritonavir with or without Ribavirin for 12 weeks in participants with chronic hepatitis C infection.